-
Product Insights
NewGap Junction Alpha 1 Protein – Drugs In Development, 2024
The Gap Junction Alpha 1 Protein pipeline drugs market research report outlays comprehensive information on the Gap Junction Alpha 1 Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ophthalmology, Cardiovascular, Oncology, and Dermatology which include indications of Diabetic Macular Edema, Dry (Atrophic) Macular Degeneration, Myocardial Ischemia, Stroke, Solid Tumor, Bone Cancer, Pressure Ulcers, and Scar. It...
-
Product Insights
NewGap Junction Beta 2 Protein – Drugs In Development, 2024
The Gap Junction Beta 2 Protein pipeline drugs market research report outlays comprehensive information on the Gap Junction Beta 2 Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ear Nose Throat Disorders which include indications of Hearing Disorders, and Presbycusis. It also reviews key players involved in Gap Junction Beta 2 Protein targeted therapeutics development with...
-
Innovation Ranking
Innovation Ranking – The Gap Inc
The Gap Inc (Gap) is an Omni-channel retailer. The company merchandises apparel, accessories and personal care products for men, women and children through its retail stores, franchised stores, and e-commerce portals. Its products are marketed under Gap, Old Navy, Banana Republic, GapFit, GapBody, GapKids, babyGapy and Athleta brand names. Gap also offers various Omni-channel services such as curbside pick-up, buy online pick-up in store, order-in-store, find-in-store, and ship-from-store. It also provides license to various third parties to sell and market...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALMB-0168 in Bone Metastasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALMB-0168 in Bone Metastasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALMB-0168 in Bone Metastasis Drug Details: ALMB-0168 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aminolevulinic Acid Hydrochloride in Human Papillomavirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aminolevulinic Acid Hydrochloride in Human Papillomavirus Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aminolevulinic Acid Hydrochloride in Human Papillomavirus Infections Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aminolevulinic Acid Hydrochloride in Cervical Intraepithelial Neoplasia (CIN)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aminolevulinic Acid Hydrochloride in Cervical Intraepithelial Neoplasia (CIN) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aminolevulinic Acid Hydrochloride in Cervical Intraepithelial Neoplasia...
-
Sector Analysis
NewBronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
Bronchiectasis Market Report Overview The Bronchiectasis market across the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) was valued at $1.4 billion in 2023 and the market will grow at a CAGR of more than 3% from 2023 to 2033. The 7MM (China, Japan, the United Kingdom, Spain, Italy, Germany, France, and the US). The market growth is attributed to the launch of brensocatib and an increase in the number of diagnosed prevalent cases of bronchiectasis. Bronchiectasis Market...
-
Sector Analysis
NewAttention Deficit Hyperactivity Disorder (ADHD) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Attention Deficit Hyperactivity Disorder (ADHD) Market Report Overview The ADHD market across the 7MM was valued at $11.9 billion in 2022. The market will decline at a CAGR of less than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan. Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with specific criteria for children and adults. ADHD is characterized by age-inappropriate, extreme, and impairing levels of inattention and/or hyperactivity and impulsivity. It is...
-
Sector Analysis
NewAmyotrophic Lateral Sclerosis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2029
Amyotrophic Lateral Sclerosis Market Report Overview Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a severely debilitating, rare, and ultimately fatal neurodegenerative condition caused by a combination of genetic and environmental factors. However, the causative pathogenic mechanisms in ALS remain unclear. The condition is characterized by progressive degeneration of both upper (UMNs) and lower motor (LMNs) neurons that leads to death, frequently from respiratory failure, within a few years. The 8MM includes the US, France, Germany,...
-
Sector Analysis
NewWest Africa Gold Mining Market by Reserves and Production, Assets and Projects, Fiscal Regime with Taxes, Royalties and Forecast to 2030
West Africa Gold Mining Market Report Overview West African gold production is estimated to be 11.83 million ounces (moz) in 2024. The region has emerged as a key gold mining hub with major contributions from Ghana, Burkina Faso, the Republic of Guinea, and Mali. Looking ahead, gold production from these major markets is expected to decline at a CAGR of more than 1% over the forecast period (2025-2030) owing to political instability and unregulated illegal mining. However, other West African...